In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Grunenthal gets lesinurad rights in Europe and Latin American from AZ

Executive Summary

AstraZeneca PLC granted Grunenthal GMBH exclusive rights throughout Europe and Latin America to develop and commercialize Zurampic (lesinurad), a urate transporter 1 (URAT1) inhibitor approved to treat hyperuricemia in adults with uncontrolled gout. Grunenthal also gets rights to an allopurinol/lesinurad fixed-dose combination in Phase III trials for the same indication.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies